| Ad Title: |
Diabetic Macular Disease |
| Study Title: |
A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus. |
| Protocol Number: |
082007-008 |
| Department(s) involved in the Study: |
Ophthalmology
|
| Purpose of the Study: |
Diabetic Macular Edema (DME) is a form of diabetic retinopathy. DME consists of swelling or edema of the macular, the central part of the retina that mediates high-resolution vision. The study investigators will assess the efficacy and safety of monthly intravitreal injections of Lucentis compared with monthly sham injections for the treatment of clinically significant macular edema with central involvement secondary to diabetes mellitus (Type 1 or Type 2). |
| Participant Eligibility: |
Please contact the study coordinator for detailed study eligibility criteria |
| Disease/Condition Under Study: |
Retinopathy (retinal disease) secondary to Diabetes Type I and II |
| Cancer Related Study: |
No
|
| Study Drug(s): |
Lucentis (ranibizumab injection)
|
| Study Device(s): |
|
| Study Doctor: |
Dr. Yuguang He |
| Location of Study: |
|
Sites
|
Recruiting at this Site
|
|
Aston Ambulatory Care Center
|
Yes
|
|
UT Southwestern Medical Center
|
Yes
|
|
| Contact Phone: |
214-645-2015 |
| Email: |
Jessica.Janecek-Griffin@UTSouthwestern.edu |
| Other Information: |
|
| Website Keywords: |
Ophthalmology
|
| Medical Keywords: |
diabetes type I, diabetes type II, diabetic, eye blindness, ocular, ophthalmic, retinal disease, retinopathy
|
